Paris, March 22, 2021 – Hybrigenics has prioritized funding proposed by the company IRIS solution that offers very attractive financial conditions, including the absence of commission and complete flexibility with the ability to terminate without charge to print at any time. These funds will allow, like a SPAC1, to seize investment opportunities with significant returns on investment. Hybrigenics targets companies with innovative technologies in the world of personalized medicine, which represent the future in terms of health or aesthetics
